



**IPSOGEN**  
CANCER PROFILER

# PRESS RELEASE

## IPSOGEN TO BE RENAMED QIAGEN MARSEILLE ON THE FIRST OF JANUARY 2013

Results of the General Assembly of 14 November 2012

Perspectives for 2013

**Marseille, November 29, 2012** - IPSOGEN (Alternext - FR0010626028 - ALIPS) is announcing the results of their Combined General Assembly of November 14, 2012.

During the assembly, some important measures were submitted to the shareholders for approval. Foremost among these measures was the integration of IPSOGEN's distribution networks into those of QIAGEN. All these measures were unanimously approved. Details of the votes are available on IPSOGEN's website (<http://www.ipsogen.com/en/investorroom/documentation-center/general-meeting-of-shareholders-documents>).

On January 1<sup>st</sup>, 2013, IPSOGEN S.A. will change its Company name to QIAGEN Marseille S.A. From this date, the sales of IPSOGEN products will be through the combined teams which will act under the QIAGEN name. The IPSOGEN<sup>®</sup> will continue as the product brand name.

The IPSOGEN management team believes that IPSOGEN can well benefit from the strong position of the QIAGEN Group on the market of human health diagnostics and from broad technology, assay and platform portfolio and its global sales network. The implementation of this new system of distribution results from an Agreement ("Distribution Agreement"), excluding Japan, between the Company and the QIAGEN Group, to take effect on January 1<sup>st</sup>, 2013.

Corinne DANAN, Vice President of IPSOGEN Sales Operations commented: *"Now IPSOGEN will be able to take full advantage of the international sales power of its largest shareholder QIAGEN, which directly covers 28 countries and has a proven distribution network in 70 other countries. The combined range IPSOGEN-QIAGEN targeting hospital and private oncology laboratories will comprise a unique offer and open competitive development prospects in an ever intensifying competitive field given the emerging market in personalized medicine. Finally, we can offer a complete solution for laboratories beyond tests alone, since QIAGEN is a world leader in the field of sample preparation for molecular analysis with a range of reagents and instruments that allow laboratories to automate their tests, making their activity more profitable. IPSOGEN products are already compatible with QIAGEN's automation solutions and will therefore also benefit from this complete product + instruments offer that will be extremely competitive."*

Vincent FERT, CEO and co-founder of IPSOGEN stated: *"This agreement significantly improves IPSOGEN's sales coverage, positioning its products within a comprehensive offer in terms of guidance and integration into a range of automation solutions to meet the needs of existing and future IPSOGEN clients. The name change from IPSOGEN to QIAGEN Marseille will provide our partners with a strong and consistent marketing message and will take advantage of the QIAGEN brand image. In addition, the QIAGEN Group will support the ongoing IPSOGEN development programs, particularly with regard to our flagship biomarkers BCR-ABL and JAK2. QIAGEN will further promote JAK2 to its pharmaceutical partners to be used as a companion diagnostic test for drugs under development. This is a major use for the development of personalized medicine and potentially a very interesting source of revenue."*

He added: *"We are delighted that our individual shareholders supported our decisions for the future of IPSOGEN and would like to thank them for their support."*



**IPSOGEN**  
CANCER PROFILER

# PRESS RELEASE

## About IPSOGEN

IPSOGEN, "Cancer Profiler," develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path.

With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with blood cancer, IPSOGEN is also targeting breast cancer. Its goal will be to provide diagnostic information that remained unavailable until now.

IPSOGEN is, since July 2011, a subsidiary of the QIAGEN group.

At end of June 2012, IPSOGEN employs 76 persons. It is headquartered in Marseille, France.

For further information, visit [www.ipsogen.com](http://www.ipsogen.com).

## Contacts

---

### IPSOGEN

**Vincent Fert**

CEO

Tel: + 33 (0)4 9129 3090

[fert@ipsogen.com](mailto:fert@ipsogen.com)

**ATCG Press**

Communication

& Press relations

**Marielle Bricman**

Tel : + 33 (0)6 26 94 18 53

[ipsogen@atcg-partners.com](mailto:ipsogen@atcg-partners.com)

**ALIPS**  
**LISTED**  
**NYSE**  
**ALTERNEXT**